Spot on DFRAI! After reading the posts yesterday trivializing expectations on AVXL ever getting to $500 per share in the foreseeable future, I had the very same thought about the potential $40B+ offer for SGEN by Merck (discussed on the front page of the WSJ and a factor that boosted the Biotech group yesterday). A successful Phase 2b/3 AD readout that catapulted Blarcamesine into the standard of care for Alzheimer's over the short/intermediate term could certainly push AVXL to a similar revenue level and valuation by 2025. The $40B+, BTW, translates into roughly $500 per share. Investors should take things one step at a time, but the potential prize is indeed huge.
News 
Market Data 
Discover 
